Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2019

Restoration of Contractile Protein Expression and Colonic Smooth
Muscle Function by Hydrogen Sulfide in DMD Mice
Kulpreet Singh
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Medical Education Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/5790

This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass.
For more information, please contact libcompass@vcu.edu.

Restoration of Contractile Protein Expression and Colonic Smooth Muscle Function by
H2S in Duchenne Muscular Dystrophy Mice

A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University

by
Kulpreet Singh
Bachelor of Science, Professional Science & Biology, Virginia Commonwealth University, 2017

Director:
S. Murthy Karnam Ph.D.
Professor, Department of Physiology and Biophysics

Virginia Commonwealth University
Richmond, Virginia
April, 2019

1

Acknowledgements

I would like to firstly thank my parents, Kuldeep and Jasvinder Slach, as well as my sister,
Angel Slach, for their undying love and support as I successfully completed all of my academic
endeavors.
Now I cannot over-exaggerate the appreciation and gratitude I have for being able to learn
and conduct research in one of the leading labs associated with gastrointestinal research a VCU. It
has been enlightening to be able to work under such leaders in the research field. I am thankful to
my fellow lab mates Adam, Molly, Gurpreet, Hangxia, and Shanwei for making such a positive
work environment. Dr. Sunila Mahavadi taught me almost everything I needed to know for my
project, helping me initiate my experiment on time and understand the process as I work along. As
for the two greats, Dr. Karnam and Dr. Grider, what I say about them could never be enough. Dr.
Karnam is probably one of the smartest people I have ever known, while being helpful and patient
with his students. His sense of humor and reassurance throughout the frustrating moments I had
during some experiments motivated me at every moment. As for Dr. Grider, he sets the positive
culture of the lab, teaching me how to approach research, career, and life in a very easy-going, fun,
yet successful manner. I am very thankful for all the memories we have made
I thank them both for their support and understanding as I tried my best to keep the
centrifuge running. I hope in the future, I will be able to come back as a medical student and
physician and be able to learn other valuable lessons from their lab again.

2

Table of Contents
Page
Acknowledgements.

2

List of Figures

5

Abstract

7

Chapter 1: Introduction

`

1.1: Background Duchenne Muscular Dystrophy

9

1.2: Dystrophin Introduction- Background, Function, and Pathogenesis

10

1.3: Dystrophin in Skeletal Muscle

12

1.4: Dystrophin in Cardiac Muscle

13

1.5: Dystrophin in Smooth Muscle

14

1.6: Overview of Gastrointestinal Tract Function and Anatomy

16

1.7: Anatomy of Gastrointestinal Wall

17

1.8: Motility Functions of the Colon (Large Intestine)

18

1.9: Smooth Muscle Structure with Contractile Protein Emphasis

19

1.10: Excitation-Contraction Coupling and Thin Filament Associated Proteins

20

1.11: Excitation-Transcription Coupling

24

1.12: Muscular Dystrophy-Abnormal GI Motility

25

1.13: Oxidative Stress

26

1.14: Hydrogen Sulfide (H2S)

27

1.15: Mouse Models of mdx

29

1.16: Rationale

30

Chapter 2: Materials and Methods
2.1: Reagents

32

2.2: Animals

32
3

2.3: H2S Treatment

33

2.4: Collection/Preparation of Colonic Tissue

33

2.5: Preparation of Dispersed Smooth Muscle Cells

34

2.6: Measurements of Contraction in Muscle Strips

35

2.7: Measurement of Contraction in Dispersed Smooth Muscle Cells

35

2.8: Qualitative Real-Time PCR Analysis (qRT-PCR)

36

2.9: Western Blot Analysis

37

2.10: Statistical Analysis

38

Chapter 3: Results
3.1: Effect of DMD on Smooth Muscle Contraction and Relaxation

39

3.2: Changes in Expression of Thin-Filament Associated Proteins

43

Chapter 4: Discussion

50

References

65

4

List of Figures

1: Diagram of Dystrophin

12

2: Schematic of Smooth Muscle Contraction Signaling

21

3: Ach-Induced Contraction in Colonic Muscle Strips of Mdx Mice

46

4: Ach-Induced Contraction in Colonic Muscle Strips of mdx/mTR mice and the
effect of H2S Treatment on Smooth Muscle Contraction
5: SNP-induced Relaxation in Colonic Muscle Strip of Mdx Mice

47
48

6: SNP-induced relaxation in Colonic Muscle Strips of Mdx/mTR mice and
H2S Treated Mice
7: Initial Ach-Induced Contraction in Dispersed Colonic Smooth Muscle Cells

49
50

8: Sustained Ach-Induced Contraction in Dispersed Colonic
Smooth Muscle Cells

51

5

9: SNP-Induced Relaxation in Dispersed Colonic Smooth Muscle Cells of Mdx
Mice

52

10: ISO-Induced Relaxation in Dispersed Colonic Smooth Muscle Cells of Mdx
Mice
11: mRNA and Protein Expression of Caldesmon in Colon of Mdx mice

53
54

12: mRNA Expression of Caldesmon in Colon of mdx/mTR mice
and the Effect of H2S Treatment on expression
13: mRNA and Protein Expression of Calponin in Colon of Mdx mice

55
56

14: mRNA Expression of Calponin in Colon of mdx/mTR mice
and the Effect of H2S Treatment on expression

57

15: mRNA and Protein Expression of Tropomyosin in Colon of Mdx mice

58

16: mRNA and Protein Expression of Smoothelin in Colon of Mdx Mice

59

6

ABSTARCT

Duchenne Muscular Dystrophy (DMD), characterized by the lack of dystrophin, results
from a mutation in the Xp21 gene which encodes for the protein dystrophin that links the
extracellular matrix to the actin cytoskeleton in skeletal, cardiac and smooth muscle. Slow colonic
transit and chronic constipation are common in DMD patients due to the weakening of the
abdominal wall muscles and gut smooth muscle. However, the cause of this hypocontractility in
DMD patients and the expression of contractile proteins in smooth muscle are unknown.
Expression of contractile proteins is regulated by the signaling pathways activated by excitatory
(e.g., acetylcholine, ACh) and inhibitory transmitters (e.g., nitric oxide). Hydrogen sulfide (H2S)
is well-known for its anti-oxidant effects; however, its utility to restore DMD-induced effects is
unknown. Aim: To investigate the expression of contractile proteins and smooth muscle function
in the colon of wild type mice and models of DMD (mdx and mdx/mTR mice) and the effect of
H2S on these in mdx mice. Methods: Contraction of colonic segments was measured in the
longitudinal orientation from 3-month old control and mdx mice, and 9-month old control and
mdx/mTR mice, (mdx/mTR exhibit increased disease severity). The effect of SG1002, an orally
active slow releasing H2S agent, was tested in mdx/mTR mice (40 mg/kg body weight in
chow/every 3 days starting from 3 weeks to 9 months). Expression of contractile proteins was
7

measured by qRT-PCR and western blot. Results: Expression of smoothelin, caldesmon, calponin
and tropomyosin was decreased in colonic smooth muscle of mdx mice compared to control. This
decrease was associated with a decrease in ACh-induced contraction in colonic segments (21 ± 3
mN/100 mg tissue in control and 3 ± 1 mN/100 mg tissue in mdx mice). To identify the specific
involvement of smooth muscle dysfunction in the decrease in contraction, colonic muscle cells
were isolated and contraction in response to ACh was measured by scanning micrometry and
expressed as the percent decrease in cell length from control cell length. ACh-induced contraction
was also inhibited in muscle cells isolated from mdx mice compared to control (43±5% in control
and 27±3% in mdx mice). ACh-induced contraction was decreased in colonic segments from
mdx/mTR mice (12 ± 2 mN/100 mg tissue in control versus 4 ± 1 mN/100 mg tissue in mdx/mTR)
and the decrease was partly reversed by SG1002 treatment (9 ± 1 mN/100 mg tissue). mRNA
expression of thin filament associated proteins was also decreased in colonic smooth muscle from
mdx/mTR mice and the decrease was reversed by SG1002. These results suggest that H2S restores
contractile protein mRNA expression and contraction in mdx/mTR mice. Conclusion: The data
indicate that the lack of dystrophin in mdx mice adversely affects colonic smooth muscle
contractility through the down regulation of contractile protein mRNA expression. Treatment of
mdx/mTR mice with H2S restores contractile phenotype. Thus, H2S treatment would be an area of
study in therapeutic control of DMD-induced gastrointestinal motility disorders.
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Chapter 1: INTRODUCTION

1.1: Background Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD) is a rapidly progressive neuromuscular and
X-linked disorder that affects 15.9 to 19.5 per 100,000 live births, characterized by muscle
weakness with eventual disability (Yucel et al., 2018) (Ryder et al.2017). It is caused by
mutations in the gene located at Xp21, which encodes for the protein dystrophin.
Continuous muscular damage and muscle fiber degeneration is evident in patients suffering
from DMD, causing muscular weakness that is associated with motor delays, loss of
ambulation, respiratory impairment and cardiomyopathy (Birnkrant et al., 2018). Effects
of this genetic disorder are apparent in individuals early on from ages 1-3 through
symptoms such as delayed walking, frequent falls, and difficulty climbing stairs due to the
effects that a lack of dystrophin has on the muscular system (Ryder et al.2017). In terms
of the gastro-intestinal system, chronic constipation is highly prevalent and an ongoing
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source of discomfort and distress in DMD patients- this is specifically due to the struggles
of GI motility caused by the manifestation of the DMD phenotype on gastrointestinal
smooth muscle (Brumbaugh et al., 2018) (Lo Cascio et al., 2016). Chronic constipation in
DMD patients requires the regular use of laxatives and enemas, promoting life-threatening
metabolic acidosis through the loss of bicarbonate, furthering the complications associated
with the consequences of DMD (Lo Cascio et al., 2014). Most people with DMD die from
cardiac failure before or during their 30s as the cardiomyopathy that develops in DMD
causes the heart chambers of individual to enlarge and the walls to thin out, ultimately
leading to the development of heart failure (Ryder et al., 2017). Although death is
inevitable, the gastrointestinal effects of DMD result in a very poor quality of life for
patients suffering from the disease.
1.2: Dystrophin Introduction- Background, Function, and Pathogenesis
DMD is caused by mutations in the gene that encodes for the 427-kD cytoskeleton
protein dystrophin (Nowak & Davies 2004). The dystrophin gene is the largest in the
human genome, consisting of 2.6 million base pairs of DNA and 79 exons. The full-length
dytrophin isoform, dp427, is generated from three distinct, tissue specific promoters: the
(M) muscle type promoter that drives expression of dystrophin in all three muscle groups,
the brain-type (B) promoter that drives dytrophin expression in cortical and cerebellar
neurons and the heart, and the purkinje type (P) promoter that drives cerebellar dystophin
expression (Petkova et al., 2016). Around 60% of the mutations of dystrophin are due to
large insertions or deletions that lead to further downstream frameshift errors (Nowak &
Davies 2004).
10

Structurally, the dystrophin protein plays a critical role in muscles in linking the
intracellular actin cytoskeleton of a myocyte to the extracellular matrix via the dystrophin
associated protein complex (DAPC), protecting the sarcolemma from contractile stress
(Blake et al., 2002) (Petkova et al., 2016) (Petrof 2002). Dystrophin contains four main
functional domains: an amino (N) terminus that connects to the intracellular F-actin
cytoskeleton, the central rod domain that contains spectrin-like repeats, the cysteine rich
domain, and the carboxyl terminus that binds the DAPC, providing the link between the
intracellular cytoskeleton and the ECM (Guiraud et al., 2015) (Renzhi et al., 2011) (Wang
et al., 2016). The spectrin-like repeats of dystrophin’s rod like domain predict that
dystrophin may function as a shock absorber, resisting multiple rounds of muscle
contraction and relaxation (Guiraud et al., 2015). Furthermore, dystrophin itself assembles
several transmembrane proteins and cytoplasmic proteins into the DPAC, which is divided
into: the dystroglycan complex, sarcoglycan complex, and cytoplasmic and ECM
components. Ultimately, the DAPC connects the cytoskeleton with the ECM, leading to
the mechanical stability of the sarcolemma and protection against contraction-induced
muscle damage (Petkova et al., 2016). The vast majority of patients with DMD completely
lack dystrophin; however, even with reduction in the amount or alteration in the size of the
dystrophin gene leads to a less severe type of muscular dystrophy of Becker’s Muscular
Dystrophy, suggesting the crucial impact dystrophin has on the muscular system (Nowak
& Davies 2004).
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Figure 1. Diagram of Dystrophin (Kamdar 2016 JACC). Schematic diagram of DGC
(dystroglycan complex). DGC is seen to span the sarcolemmal membrane and link the cytoplasmic
actin cytoskeleton to the ECM via dystrophin. The DGC includes sarcoglycans, β-dystroglycan,
and extracellular α-dystroglycan. Cytoplasmic components include dystrophin which binds to
dystrobrevin, syntrophin, and nitric oxide synthase.
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1.3: Dystrophin- Skeletal Muscle
Skeletal muscles are dynamic tissues that undergo stress from each contraction. The
connection between the cytoskeleton of the muscle cell and the ECM is imperative for
maintaining cellular integrity and function during each cycle of contraction and stress
(Guiraud et al., 2015) (Renzhi et al., 2011) (Wang et al., 2016). In completely regular, nonaffected skeletal muscles, the susceptibility for mechanical damage is ongoing; however,
homeostasis is maintained through injury repair by muscle stem cells and satellite cells. In
DMD, DAPC, which is responsible for the physical connection of the sarcolemmal
cytoskeleton with the ECM, loses its ‘structural linkage’ due to the loss of dystrophin,
making the sarcolemma prone to further damage by mechanical stress and leaving the
repair processes incapable of maintaining homeostasis (Beyers et al., 1993). Now during
contraction, there is sarcolemmal damage, an increase in membrane permeability to Ca++
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and small ions, leading to cell death and dysfunction. This imbalance between skeletal
muscle degeneration to regeneration initiates the process of fibrosis via inflammatory
processes, which is a hallmark of DMD (Guiraud et al., 2015) (Han et al., 2011).
Histologically, normal skeletal muscles consist of muscle fibers that are evenly spaced,
angular, and uniform in size; on the contrary, DMD muscle biopsies show necrotic and
degenerative muscle fibers, with the lost muscle myofibers being replaced by connective
tissue and fat (Blake et al., 2002) (Guiraud et al., 2015).

1.4: Dystrophin- Cardiac Muscle
95% of patients with DMD develop cardiomyopathies by the age of 20, and cardiac
failure is one of the major sources of mortality in DMD patients, with respiratory failure
being the other (Birnkrant et al., 2018) (Mourkioti et al., 2013) (Kaprielian and Severs
2000). Cardiac muscles of DMD patients either completely lack dystrophin or have a
truncated version of the protein. It is understood that dystrophin plays a role in linking the
cytoskeleton to the ECM via DAPC (Mourkioti et al., 2013). It is the cytoskeleton that
allows cardiomyocytes to a maintain their characteristic shape and structure despite the
contraction-induced damage imposed on the cardiac muscle cells from the cyclic
contractions of the heart (Mourkioti et al., 2013) (Kaprielian and Severs 2000) (Kuo and
Ehrlich 2015).
Compared to skeletal muscles, dystrophin in cardiomyocytes is not only distributed
along the sarcolemma, but also the transverse tubules, where it is not seen in the skeletal
muscles (Kaprielian and Severs 2000) (Kaprielian et al., 2000) (Byers et al., 1991).
14

Dystrophin is also absent from the membrane that overlays the adheren junctions of the
intercalated discs (Byers et al., 1991) (Kaprielian and Severs 2000).
Dystrophin’s structural role in providing membrane stability and increased
mechanical strength of the myocyte membrane, it is well understood that in
cardiomyocytes, like in skeletal muscles, it plays an important role in regulating the force
of transmission in cardiomyocytes during the cyclic process of contraction in the heart
(Kaprielian and Severs 2000) (Kaprielian et al., 2000) (Shirokova and Niggli 2013).
Nevertheless, the distribution of dystrophin along the T-tubules suggests that dystrophin
serves roles more than just contractile force as T-tubules are not directly affected by
membrane distortion during cardiac contraction (Kaprielian and Severs 2000) (Kaprielian
et al., 2000).

1.5: Dystrophin- Smooth Muscle
In smooth muscle cell membranes, dystrophin is not seen to be distributed uniformly
across the SMC membrane, but more distantly and discontinuously (Beyers et al., 1991)
(North et al., 1993). More specifically, dystrophin is seen to be dispersed in the caveolaerich domains of the smooth muscle cells (North et al., 1993).
During the contraction of smooth muscles, the mechanical damage from muscle
contraction falls upon the sarcolemma, where just as in skeletal and cardiac muscles,
dystrophin provides the mechanical support to the SMC membrane via anchorage of the
cytoskeleton to the ECM. Nonetheless, the distribution of dystrophin in caveolae-rich
domains predicts interaction between these two structures, suggesting that dystrophin may
15

also act as a tension-sensing molecule that conveys information about sarcolemmal stress
to the mechanosensitive Ca++ channels (Beyers et al., 1991).
A distinct feature found on contractile SMCs is the abundance of caveolae,
exceeding 160,000 in number on a single SMC. Caveolae contribute to mechanisms that
modulate contractile and proliferative activity with SMCs. They contain caveolins that are
needed for scaffolding and signal-transduction (Halayko and Stelmack 2005). Caveolin-1
attaches to the intracellular tail of B-dystroglycan, the core transmembrane subunit of the
dystrophin-glycoprotein complex (DGC/DPAC), which is linked to the intracellular actin
via dystrophin and ECM laminin via a-dystrogycan. Caveolin-1 and dystrophin overlap at
the membrane of contractile SMCs, where one of the key roles of dystrophin/DGC is to
stabilize the plasma membrane to protect it against any damaging contraction-induced
force. The close association of caveolins with DGC and cytoskeleton may also play a
unique role in mediating and stabilizing the ordered compartmentalization of caveolae on
the plasma membrane (North et al., 1993) (Beyers et al., 1991) (Halayko and Stelmack
2005).
Disruption of DGC due to the loss of dystrophin leads to DMD; however, abnormal
number, size, and shape of caveolae is also evident in DMD, suggesting that dystrophin is
not only essential for providing protection against contractile stress, but also the
organization of caveolae on the plasma membrane; an incompetent DGC from dystrophin
loss leads to the compromise of caveolae compartmentalization (Halayko and Stelmack
2005).
1.6: Overview of Gastrointestinal Tract Structure and Function
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The GI tract consists of a series of hollow organs that span from the oral
cavity/mouth to the anus, with several accessory organs and glands that add secretions to
these hollow organs. Each of these hollow organs are separated by sphincters, which allows
these organs to have specialized functions. The mouth and the oropharynx are responsible
for the mechanical digestion of dietary substances via mastication (chewing), lubrication
of the food, initiation of carbohydrate and lipid digestion via salivary amylase and lingual
lipase and propelling the food into the esophagus. The esophagus acts as conduit to the
stomach, through which the bolus enters the stomach. The stomach temporary stores food
and initiates mechanical digestion of dietary substances through churning, and chemically
digests food through protease and hydrochloric acid (HCl) secretions. Once gastric
contents are mixed with the hydrochloric acid and do not exceed a diameter of 2 mm,
chyme is orderly transferred to the proximal small intestine (duodenum) through the
pyloric sphincter, followed by peristaltic migration distally to the jejunum and then then
the ileum. The small intestine is the ‘hotspot’ for nutrient absorption and continues the
general digestive processes. Pancreatic enzymes/secretions and brush border enzymes of
the small intestine complete digestion by breaking down dietary contents in the correct
chemical form that allow for intestinal absorption. Contents of indigestion enter the colon,
and travel through the cecum, ascending colon, transverse colon, descending colon, and
sigmoidal colon, culminating in the rectum before it has amassed sufficiently to be excreted
from the anus.
Accessory organs and glands include the salivary glands, pancreas, and liver. The
salivary glands secrete saliva, salivary amylase, and lingual lipase, all of which contribute
17

to the digestion of carbohydrates and lipids in the oral cavity. The pancreas secretes
pancreatic enzymes such as chymotrypsin, amylase, and lipase for the digestion of proteins,
carbohydrates, and lipids. In addition, it also secretes bicarbonate (HCO3-) to neutralize the
incoming gastric acid from the stomach. Bile is produced in the liver and stored in the
gallbladder for future delivery in the duodenum for lipid digestion/emulsification.

1.7: Anatomy of Gastrointestinal Wall
The alimentary canal is arranged into certain organizational layers that are common
to all segments of the tract. Surrounding the luminal space of the GI tract is the mucosal
layer that consists of an epithelial layer, an underlying layer of loose connective tissue
called the lamina propria that contains enteric neurons, immune cells, and capillaries, and
thin layer of smooth muscle known as the muscularis mucosae. Enclosing the mucosa is
the submucosa, a layer of loose connective tissue that contains a larger vasculature than the
lamina propria, along with the submucosal plexus (enteric neurons), and glands such as
Brunner’s glands that secrete substances into the GI lumen. The submucosa is surrounded
by the muscularis externa, that consists of an inner circular muscle layer and an outer
longitudinal muscle layer. Both are responsible for peristalsis, which is characterized by a
progressive wave of relaxation, followed by contraction. The serosa is an enveloping layer
of connective tissue lined with mesothelium composed squamous epithelial cells, covering
intraperitoneal organs. On the contrary, the adventitia is the outermost connective tissue
layer that covers retroperitoneal organs anchored to the posterior abdominal wall.
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1.8: Motility Functions of Colon (Large Intestine)
Colonic contractions are regulated by myogenic, neurogenic, and hormonal factors.
Parasympathetic control of the proximal two-thirds of the colon is mediated by the vagus
nerve, whereas the parasympathetic control of the descending and rectosigmoid colon is
mediated via pelvic nerves originating from the sacral spine.
The proximal colon has two types of motor activity, non-propulsive segmentation
and mass peristalsis. Non-propulsive segmentation is generated by slow-wave activity that
produces circular-muscle contractions that churn and mix the ingesta, presenting them to
the mucosa where absorption occurs and moving them in an caudad direction.
Antiperistaltic contractions propagate toward the ileum, hampering the movement of the
colonic contents through the colon, and allowing further absorption of water and
electrolytes. These segmental contractions are what give the large intestine its typical
haustra appearance. Haustra are small pouches caused by sacculation, giving the colon its
segmented look. The colonic contents during segmental mixing are retained in the proximal
large intestine for long periods as fluid and electrolyte absorption continues- giving the
large intestine its reservoir function. Mass peristalsis occurs when the colonic contents are
propelled distally 20 cm or more, representing the major form of propulsive motility in the
colon.
The distal colon is primarily characterized by non-propulsive segmentation. It is in
this distal colon that the final desiccation of colonic contents occurs and where these
contents are stored prior to an occasional mass peristalsis that propels them into the rectum.
19

The rectum itself is kept nearly empty by non-propulsive segmentation until it is filled by
mass peristalsis of the distal end of the colon. Filling of the rectum triggers a series of
reflexes in the internal and external sphincters that ultimately lead to defecation.

1.9: Smooth Muscle Structure with Contractile Protein Emphasis
Smooth muscles are distributed in the walls of various organs and systems, ranging
from blood vessels, stomach, intestines, bladder, airways, uterus, and the penile and clitoral
cavernosal sinuses (Webb 2003). Smooth muscle cells lack the striated banding pattern
found in cardiac and skeletal muscles and receive neural innervation from the autonomic
nervous system. The contractile state of the smooth muscle is controlled by hormones,
autocrine/paracrine agents, and other local chemical signals. Changes in load or length also
develop the tonic and phasic contractions of the SMC’s. Regardless of what stimulus
regulates the contractile state in SMC’s, the cross-bridge cycling between actin and myosin
is what ultimately develops force, with Ca++ ions initiating contractions (Gunst and Tang
2000).
The contractile apparatus of smooth muscles is very similar to skeletal but is not as
highly organized into discrete sarcomeres as in the striated muscles. Thick myosin
filaments and thin actin filaments are the primary constituents of the smooth muscle
contractile apparatus, colocated in the contractile domain of the cell (Horowitz et al., 1996)
(Morgan and Gangopadhyay 2001) (Wang et al., 2012).
Thin filaments are 6-8 nm in diameter and contain actin, which exists as F-actin in
vivo, as their main protein constituent. Furthermore, the cellular content of actin in smooth
20

muscle is ~ twice that of striated muscles. It is well understood that actin-myosin
interaction initiates contraction in all three muscle groups; however, there are thin-filament
regulatory proteins in smooth muscle that associate with actin and modulate cross-bride
function but are understood at a lesser extent (Babu et al., 2000).
Thick filaments are bipolar assemblies composed of multiple myosin molecules.
Each myosin aggregate is composed of two intertwined heavy chains (SM-MHC), a pair
of 17-kDa non-phosphorylatable alkali light chains (ELC), and a pair of regulatory 20-kDa
light chain (MLC20). The myosin heavy chain dimers form globular amino terminal heads
and coiled-coil tails at their carboxy terminus. The myosin head has an intrinsic actinactivated Mg2+ ATPase activity, through which myosin is able to transform the chemical
energy stored in ATP to mechanical work associated with smooth muscle contraction.
Mucle contraction is driven by the cyclical interaction between the myosin thick filament
and actin thin filaments coupled with ATP hydrolysis (Farah and Reinach 1995). A cross
bridge is formed between the actin and myosin, that produces force and movement as it
‘tilts’ into subsequent bound states until finally detaching (Babu et al., 2000) (Viegal et al.,
2003).

1.10: Excitation Contraction Coupling and Thin Filament-Associated Proteins
In all three muscle types, an increase in [Ca++]i triggers contraction via the removal
of cross-bridge cycling inhibition (Farah and Reinach 1995) (Holda et al., 1998) (Horowitz
et al., 1996) (Merlini et al, 2003). An increase in intracellular Ca++ concentrations in the
21

smooth muscle initiates certain processes that ultimately increase the ATPase activity of
myosin. Binding of four Ca++ ions to calmodulin forms the Ca++-Calmodulin complex that
activates myosin light chain kinase (MLCK), responsible for phosphorylating the
regulatory 20-kDa light chain. The principal function of calmodulin in smooth muscle is
to activate cross-bridge cycling and development of force in response to the transient
increase in intracellular calcium concentration. Rather than troponin C (as in striated
muscles), calmodulin is the calcium binding protein responsible for contraction
transduction (Farah and Reinach 1995) (Holda et al., 1998) (Horowitz et al., 1996) (Merlini
et al, 2003). This phosphorylation of Ser19 on the 20-kDa regulatory light chain of myosin
is fundamental for the actin-activated myosin ATPase and interaction between actin and
myosin which initiate smooth muscle contraction (Farah and Reinach 1995) (Holda et al.,
1998) (Horowitz et al., 1996) (Kuo and Ehrlich 2015) (Walsh 1994).
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Figure 2. Smooth Muscle Contraction. This figure shows a general summary of the process of
smooth muscle contraction. The initial pathway is Ca++ and calmodulin (CaM) dependent, where
the Ca++/CaM complex activate the myosin light chain kinase (MLCK), triggering contraction via
myosin light chain (MLC20) phosphorylation. This represents the initial contraction. The sustained
pathway is Ca++/CaM independent and requires the inhibitions of myosin light chain phosphatase
(MLCP) to keep the MLC20 phosphorylated and the contraction sustained.
GPCR: G-Protein Coupled Receptor; PLC-β1: Phospholipase C β-1 ; IP3: Inositol 1,4,5triphosphate; SR: Sarcoplasmic Reticulum; Ca++: Calcium; CaM: Calmodulin; MLCK: Myosin
Light Chain Kinase; MLC20-P: 20 kD Myosin Light Chain; MLCP: Myosin Light Chain
Phosphatase; RhoA: Ras Homolog gene family, member A; ROCK: Rho associated, coiled-coilcontaining protein kinase 1; CP17: C-potentiated Inhibitor 17; PKC: Protein Kinase C;

This mechanism pertains specifically to thick filaments, and it is apparent that
smooth muscle cross-bridges are regulated by the phosphorylation of MLC20; however,
additional regulation of smooth muscle contraction through thin-filament associated
proteins is indicated. Thin-filament regulation is one of several mechanisms invoked to
explain the well-known capacity of smooth muscles to maintain tone at low MLC20
phosphorylation. These thin-filament associated proteins include: tropomyosin, calponin,
caldesmon, and smoothelin (Horowitz et al., 1996) (Morgan and Gangopadhyay 2001).
Tropomyosin. Individual tropomyosin molecules consist of two identical alpha
helices that coil around each other and sit near the two grooves that are formed by the two
helical actin strands. The head to tail contact between adjacent tropomyosin proteins results
in a continuous filament that spans around seven actin monomers (Farah and Reinach 1995)
23

(Holda et al., 1998) (Horowitz et al., 1996) (Merlini et al, 2003). The role of tropomyosin
is to interfere with the binding of myosin to actin. In skeletal muscles, through its
interaction with the troponin complex, tropomyosin acts as a Ca++ switch turning myosin
ATPase activity on and off (Farah and Reinach 1995) (Holda et al., 1998) (Horowitz et al.,
1996) (Merlini et al, 2003). In smooth muscles, tropomyosin’s role is less clear due to the
lack of troponin; however, it is suggested that tropomyosin inhibits acto-myosin ATPase
activity in smooth muscle as well, through its interaction with caldesmon17,27,33,62.
Caldesmon. Caldesmon is an actin, tropomyosin, myosin, and calmodulin binding
protein. Like the other thin-filament associated proteins, caldesmon also tonically inhibits
the ATPase activity of myosin in smooth muscle. It inhibits actin-activated Mg2+-ATPase
of smooth muscle myosin by reducing the affinity between actin and myosin. This
inhibition is a result of competition between caldesmon and the myosin head for a binding
site on actin as both can displace one another from the actin thin filament. Structurally, the
carboxy-terminal domains of caldesmon are responsible for actin binding and inhibition of
myosin ATPase activity in vitro. The amino-terminal domains bind to myosin and tethers
myosin to actin in conjunction with the C-terminal actin binding domains. There are also
two high-affinity tropomyosin binding sites on the C-terminal domain of caldesmon and
between resides 230 and 419, indicating the function caldesmon plays in tropomyosinmediated inhibition of acto-myosin ATPase activity. Furthermore, it is observed that the
presence of tropomyosin increases caldesmon-actin binding affinity (Farah and Reinach
1995) (Holda et al., 1998) (Horowitz et al., 1996) (Merlini et al, 2003) (Morgan and
Gangopadhyay 2001).
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Calponin. Calponin is another thin-filament associated protein that like caldesmon,
tonically inhibits the interaction between myosin and actin. Its function of binding to Factin and inhibition of ATPase activity are localized to its central domain. Calponin inhibits
the ATPase activity of myosin heads cross-linked to actin resulting from a conformational
change in actin induced by calponin binding and actin’s reduced capacity to activate
myosin ATPase. It contains three isoforms, h1, h2, and an acidic variant, with h1 being
smooth muscle specific (Holda et al., 1998) (Horowitz et al., 1996) (Merlini et al, 2003)
(Morgan and Gangopadhyay 2001).
Smoothelin. Smoothelin’s are actin-binding proteins that are abundantly expressed
in visceral smooth muscle as smoothelin-A, and expressed in vascular smooth muscle as
smoothelin-B47. Both isoforms of smoothelin are found only in actively contracting smooth
muscles. During pathological conditions associated with GI tract or vascular system,
smoothelin-A and smoothelin-B expression is lower with adverse effects being apparent in
the contractility of the two systems. Ultimately, it is understood that smoothelin is
imperative for optimal contractility of smooth muscle, but the mechanism through which
it accomplishes its function is not clear (Niessan et al., 2005).

1.11: Excitation-Transcription Coupling
Excitation-transcription coupling is a process that is highly dependent on [Ca++]i –
specific stimuli and activates various transcription factors that elicit transcriptional
responses depending on the conditions of the cell both extracellularly and intracellularly42.
Smooth muscle cells of the vascular system require expression of a unique range of
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contractile proteins/genes like SM-MHC, SM22alpa, calponin, smoothelin, etc (Misarkova
et al., 2016) (Wamhoff et al., 2006).
CREB (cAMP response element binding protein). CREB is highly expressed and
active in quiescent smooth-muscle cells. It promotes smooth muscle gene expression and
decreases proliferation through regulating the expression of cell cycle regulatory genes,
genes encoding for growth factors, growth factor receptors, and cytokines. cAMP/PKA
pathway, MAPK pathway, and more importantly the Ca++- Calmodulin complex, which
activates MLCK and promotes MLC20 phosphorylation to induce contraction, also
promotes the phosphorylation of CREB via CamK regulation (Wamhoff et al., 2006)
(Marchand et al., 2012).
NFAT and NFkB. NFAT transcription factors include 4 isoforms, NFAT1,
NFAT2, NFAT3, and NFAT4. These factors are activated by calcineurin, a Ca++Calmodulin-dependent phosphatase that is activated during EC/ET- coupling by myofibril
Ca++ fluctuations. The dephosphorylation of NFAT by calcineurin allows for its
translocation to the nucleus, where expression of SM-MHC and actin are increases,
suggesting its role in regulating expression of different SMC marker genes (Marchand et
al., 2012).
Ca++/CArG element. Expression of the majority of SMC markers genes like actin,
SM-MHC, SM22a, and h1 calponin have been shown to be dependent on at least one CArG
element, located in the promoter-enhancer regions of these genes, and intracellular Ca++
concentration. During depolarization-induced calcium influx through the L-type voltagegated Ca++ channels, there’s an increase in the mRNA levels of actin, SM-MHC, and
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SM22a. The L-type voltage-gated Ca++ channels activation was CArG dependent
(Marchand et al., 2012).

1.12: Muscular Dystrophy- Abnormal Gastrointestinal Motility
Various clinical manifestations such as bloating, fullness, slow colonic transit, and
chronic constipation have been reported in the gastrointestinal tract, often with lifethreatening complications. Despite postmortem evidence of significant gastro-intestinal
smooth muscle degeneration in DMD, its mechanism, GI function, and treatment have not
yet been systematically studied (Lo Cascio et al., 2016) (Mule et al., 2010). It has been
speculated that reduced slow-wave activity, along with the reduced availability of intestinal
NO (due to the lack of dystrophin) might be a possible mechanism for the reduced intestinal
motility and transit time (Lo Cascio et al., 2016) (Mule et al., 2010). Furthermore, this lack
of dystrophin causes the linkage between the cytoskeleton and extracellular matrix to
break, making muscles more susceptible to contraction-induced damage. This damage is
associated with plasma membrane tears and ruptures, causing Ca++ influx and intracellular
overload of Ca++. There are morphological signs of significant reduction in the thickness
of the muscular layer, mucosal degeneration and damage to the internal membrane of
mitochondria in the large intestine of DMD mice. Nonetheless, the cause of this damage
and reduced contractility is not fully understood (Alves et al., 2014) (Ryder et al., 2014)
(Sarna et al., 2010).

1.13: Oxidative Stress
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Oxidative stress and inflammation are proposed pathogenic mechanisms that can
explain the dystrophic pathophysiology. Smooth muscles lacking functional dystrophin
have an increased susceptibility to sarcolemmal damage after muscle contraction, leading
to necrosis and oxidative stress, where this stress seems to exacerbate the pathology of
DMD. The precise understanding of why this dystrophin deficiency causes ROS
production is not clear; however, it likely correlated with the excessive amounts of
intracellular Ca++ coupled with inflammation (Chahbouni et al., 2010).
Elevated cytosolic Ca++ levels lead to an increase in mitochondrial Ca++, which is
an effector of ATP synthesis. An increase in ATP synthesis causes an increase in the ROS
production by the mitochondria through higher O2 consumption and enhanced e- flow
through the electron transport chain (Terril et al., 2013). Membrane damage, due to the
contraction-induced damage in dystrophin deficient smooth muscles, results in the
degranulation of mast cells and release of intracellular contents, activating the immune
system. Immune cells like neutrophils and macrophages generate ROS in order to promote
phagocytosis. NFkB immunoreactivity has also been detected in the plasma, macrophages
and necrotic and non-necrotic fibers in the muscle of DMD patients. The NFkB
transcription factor plays a role in the expression of TNFa and IL-1B, which in turn
stimulate further production of ROS (Chahbouni et al., 2010) (Singh and Lin 2015).

1.14: Hydrogen Sulfide (H2S) – Physiological Effects
Smooth muscle relaxation. Hydrogen Sulfide is well-known as a poisoning and
toxic pollutant. However, just like nitric oxide NO and carbon monoxide CO, it is
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considered a gasotransmitter that induces relaxation in the smooth muscles (Mancardi et al
2009). H2S is produced both enzymatically and non-enzymatically in the GI tract. The
enzymes, cystathionine-B- lyase (CBS) and cystathionine-y-lyase (CSE), are found in the
GI tract of mice, rat, and the colon of healthy humans. These enzymes are able to produce
H2S via the reduction of cysteine. Non-enzymatic production of H2S in the GI tract is
associated with sulfur reducing bacteria present in the large intestine (Wang 2012).
The best-known physiological role for NO is as an endothelial-derived relaxing
factor (EDRF) which shows vasorelaxant actions. H2S, like NO, has been shown to induce
smooth muscle relaxation in the blood vessels as seen with hypertension development in
mice with CSE knocked out (Kimura, 2011). Relaxation of these smooth muscles occurs
mostly via the opening of ATP-dependent K+ channels58. This process of causing
vasodilation of through the opening of ATP-dependent K+ channels preconditions against
ischemia/reperfusion injury and myocardial infarction. A multitude of findings support this
concept: K+-dependent ATP channel blockers attenuated H2S induced vasodilation both in
vivo and in vitro. The relaxing effect of H2S on colonic motility has also been explained,
in part, by its direct inhibition of the L-type C++ channels. An endothelium-dependent effect
is also seen to contribute to these vasodilatory properties. In human endothelial cells, H 2S
caused direct inhibition of the angiotensin-converting enzyme and enhanced the
vasorelaxation induced by NO (Kimura, 2011) (Singh and Lin 2015).
Antioxidation. H2S also consists of a thiol group that allows it to reduce disulfide
bonds and carry out biological effects as an antioxidant. In neurodegenerative diseases, like
Alzheimer’s, H2S exerts its antioxidant function as a peroxynitrite scavenger. In the brain’s
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of Alzheimer patients, considerably low levels of H2S are noted with protein nitration by
peroxynitrite increased. When testing the effects of the ‘H2S’ donor NaSH (sodium
hydrogen sulfide) in cultured human SH-SY5Y cells, H2S significantly inhibited
peroxynitrite-mediated tyrosine nitration, peroxynitrite-induced cytotoxicity, intracellular
protein nitration and protein oxidation (Whiteman et al., 2004).
Another H2S donor/prodrug, SG1002, was used to investigate its effects on stress
induced hypertrophic signaling in murine HL1 cardiomyocytes. SG1002 increased levels
of H2S producing enzyme, CBS, as well as significantly inhibiting H2O2 and ET-1/Phe
induced oxidative stress (Whiteman et al., 2004).
Treatments. It is understood that dystrophin loss predisposes all muscle fiber types
to contraction-induced damage that ultimately leads to muscle degeneration (Lim et al.,
2017). Today, treatment for DMD uses a multidisciplinary approach as multiple organ
systems are affected, and these treatments are palliative at best- hoping to manage the
complications with ambulation, respiration, and cardiac health in DMD patients.
Prolonged, high-dose corticosteroid treatment has been most widely utilized due its
effectiveness in delaying the disease progression by specifically affecting the aspect of
muscle wasting presented in DMD (Biggar et al., 2001). Steroidal drugs such as prednisone
and deflazacort have shown to preserve muscle function, with increasing muscle mass and
slowing muscular degradation. However, the therapeutic benefits of corticosteroid
treatment are temporary, with disease progression only being delayed and various adverse
side effects such as growth retardation, weight gain, hypertension, and cataracts developing
(Hori et al., 2011) (Merlini et al 2003)
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Now, as aforementioned, oxidative stress is an important downstream signal in the
dystrophin process, particularly due to the dysregulation of intracellular Ca++ homeostasis
caused by contraction-induced damage and mitochondrial damage. The existence of this
hyper oxidative status in the DMD phenotype not only implicates the role of ROS in the
pathophysiology of DMD, but also the importance of antioxidant therapeutics for DMD
treatment. Recently, antioxidants such as resveratrol and melatonin have been used for
DMD treatment in mdx mice, and they presented a reduction in ROS levels, fibrosis,
cardiac dysfunction, and an increase in lifespan (Biggar et al 2001) (Hori et al 2011)
(Chahbouni et al 2010).

1.15: Mouse Models of DMD
Knowledge of how lack of the gene for the cytoskeleton protein dystrophin leads to
DMD has led to the development of various mouse models used for DMD research.
There are both naturally occurring and laboratory-generated animal models that are
used to study the pathophysiology of DMD and therapeutic efficacy of drugs on the disease.
Currently, there are around 60 different mouse models for DMD (Mcgreevy et al., 2015).
The standard model of DMD is the mdx mouse, which carries the mutated
dystrophin gene that is found in DMD patients. However, despite this deficiency in
dystrophin, mdx mice lack the severe clinical manifestations that are present in DMD
patients- the lifespan is only reduced by ~25% in mdx mice compared to the ~75%
reduction seen in DMD patients. There is also a well-known discrepancy in the muscular
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wasting that is displayed in DMD patients compared to the mdx mouse (Mcgreevy et al.,
2015) (Fulmer 2011).
There are, however, mice models available that overcome this discrepancy,
displaying a more severe phenotype of the DMD disease. Studies have shown that muscle
cells of DMD patients have reduced proliferative and regenerative potential than muscles
of healthy subjects’ due to telomerase shortening. In mice, there is minimal telomerase
shortening with age progression, which is implicated as a cause for the discrepancy seen
between mdx mice and DMD patients in regard to muscle degradation. Consequently, the
mdx/mTR -/- mouse model was created, which is a double knockout (KO) mouse that lacks
not only dystrophin, but also the telomerase RNA component (Terc) that maintains
chromosome telomere length. Other major DMD mouse models include: utrophin KO
mouse (mdx/Utrn -/-), α-dystrobravin KO mouse (mdx/Dtna -/-), α-7 integrin KO mouse
(mdx/α-7 -/-), and Myod1 deficient mice (mdx/Myod1 -/-) (Fulmer 2011) (Mourkioti et al
2013).

1.16: Rationale
The clinical effects of DMD in the large intestine of the gastrointestinal tract are
commonly seen in DMD affected patients and animal models yet information on the
mechanism and treatment of these complications have not been evaluated. Most of the
underlying cause of aberrant GI function is correlated with hypocontractility; however, the
cause of this hypocontractility in DMD patients and the effect that dystrophin deficiency
has on contractile protein expression in smooth muscle are unknown. H2S is a well-known
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gasotransmitter that promotes gut motility and regulates the expression of contractile
proteins by its signaling pathway as an inhibitory transmitter. Nonetheless, its effect on
colonic motility in DMD is unknown.
Hypothesis. My aim is to investigate the effect the DMD phenotype has on the
levels of thin-filament associated proteins and colonic smooth muscle contractility. I
hypothesize that the lack of dystrophin will lead to a decrease in contractile protein mRNA
expression and smooth-muscle function. Furthermore, oxidative stress is considered an
important process in the pathophysiology of DMD, thus, my aim is to also examine whether
H2S, which is known to have antioxidant function, can restore the effects of dystrophin
deficiency. I hypothesize that H2S treatment restores the effects of dystrophin deficiency.
Approach. Contraction and relaxation of colonic segments were measured in their
longitudinal orientation from 3-month-old control and mdx mice, and 9-month-old control
and mdx/mTR mice using organ bath systems. The effect of the H2S prodrug, SG1002, was
tested in mdx/mTR mice. The expression of contractile proteins in mdx and mdx/mTR mice
along with their age-matched control was measured using qRT-PCR and Western Blotting.
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Chapter 2: MATERIALS AND METHODS

2.1 : Reagents
Antibodies for Calponin, Caldesmon, and Smoothelin were obtained from Abcam
(Cambridge, MA). Antibody for Tropomyosin was obtained from Santa Cruz
Biotechnologies, Inc. (Dallas, TX); GAPDH was obtained from Cell Signaling Technology
(Danvers, MA) RNAqueousTM kit, TRIzol Reagent, High-capacity cDNA Reverse
Transcription Kit, PCR Primers for Calponin (Cnn1 Mm00487032-m1 59 bp), Caldesmon
(Cald1Mm00513995-m1 102 bp), Tropomyosin (Tpm2 Mm00437172-g1 97 bp),
Smoothelin (Smtn Mm00449973 m1 66 bp), GAPDH (NM-008084.2 107 bp), β-actin
(Actb Mm02619580-g1), and 18-S (4332641)were obtained from Thermo Fisher
(Waltham, MA); Western Blotting materials, 2x Laemmli Sample Buffer, DCTM Protein
Assay Reagents, Clarity Max Western ECL Substrate, Clarity Western ECL were obtained
from Bio-Rad Laboratories (Hercules, CA) T-PER® Tissue Protein Extraction Reagent was
obtained from Thermo Scientific (Rockford, IL). All other supplies from Sigma, (St.Louis,
MO); and Fisher Scientific, (Asheville, NC).

2.2 : Animals
3-month-old female wild-type (WT) and mdx mice (C57BL/6) were purchased from
Jackson Laboratory (Sacramento, California). The mice were housed in an animal facility
directed by the Division of Animal Resources at VCU. 9-month-old male WT, mdx/mTR,
and mdx/mTR treated mice were received from Dr. Salloum’s lab at Sanger Hall, who
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purchased their mice from the Jackson Laboratory (Sacramento, California). All
procedures were approved by the Institutional Animal Care and Use Committee (IACUC)
of the Virginia Commonwealth University.

2.3 : H2S Treatment
mdx/mTR mice in Dr. Salloum’s lab were treated with the H2S prodrug, SG1002, at
different time intervals, creating two different treatment cohorts of mice. SG1002, the
orally active slow-releasing H2S prodrug, was administered as 40 mg/kg of body weight in
chow/every 3 days in mdx/mTR mice: Early treated mice were given SG1002 from 21 days
old to 12 months, and late treated mice were given SG1002 from 7 months to 12 months
old.

2.4 : Collection of Tissue/Preparation of Colonic Tissue
Mice were euthanized by CO2 inhalation and carefully observed for signs of
complete cessation. Vertical incisions on the abdomen of the mouse model were
performed, and the colon was removed and placed in smooth muscle buffer (SMB), 1X
phosphate-buffered saline (PBS), or Krebs buffer solution, depending on the experimental
method being performed. Luminal contents of the colonic tubes were appropriately flushed
with a blunt syringe filled with SMB, PBS, or Krebs buffer. The colonic tubes were cut
opened along the meso-colon with surgical ring scissors. The mucosa was carefully scraped
from the smooth muscle layer, containing enteric neurons and smooth muscle cells
(SMC’s) via round edged forceps.
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For RNA isolation and lysate preparation, tissues were cut on ice and kept
‘hydrated’ with PBS. For smooth muscle cell isolation, tissues were placed in SMB [NaCl
120 mM, KCl 4 mM, KH2PO4 2.6 mM, CaCl2 2.0 mM, MgCl2 0.6 mM, HEPES (N-2hydroxyethylpiperazine-N’ 2-ethanesulfonic acid) 25 mM, glucose 14 mM, and Basic
Eagle Medium (essential amino mixture) 2.1% (pH 7.4)]. For organ bath studies, Segments
of colon, approximately 1 cm long, were immediately collected/removed and lacerated
along the long axis of the mesenteric border. The mucosa was abraded carefully. The
resulting longitudinal segments of colon tissue were pinned in a flat petri dish containing
warm (37°C), oxygenated Krebs buffer solution [118 mM NaCl, 4.8 mM KCl, 1 mM
MgSO4, 1.15 mM NaH2PO4, 15 mM NaHCO3, 10.5 mM glucose and 2.5 mM CaCl2 (95%
O2/5% CO2, pH 7.4, 37°C).

2.5 : Preparation of Dispersed Smooth Muscle Cells
Smooth muscle cells were isolated from the colon by sequential enzymatic
digestion, filtration, and centrifugation. Colonic tissue, carefully removed of the mucosa
and chopped via surgical shears as aforementioned, was incubated at 31°C for 10-15
minutes in SMB containing 0.1 % collagenase and 0.01% of soybean trypsin inhibitor. The
partially degraded tissue was washed once with collagenase-free SMB and permitted to
disperse spontaneously for 20 minutes. Cells were then colleceted/harvested through a 500
um Nitex every 10 minutes.
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2.6 : Measurement of Contraction in Muscle Strips
The isolated smooth muscle strips were tied at the proximal and distal end by silk
thread using caution as to not restrict the luminal portion. Each colonic segment was
longitudinally mounted between a glass rod and isometric force transducer and submerged
in an organ bath. Each organ bath was filled with either 7ml or 3.5 ml of Kreb’s (depending
on the size of the organ bath) and bubbled continuously with 95% O2 and 5% CO2 at 37°C
to maintain constant temperature in the bath systems. All the strips were raised to 0.7-0.8
grams of tension and allowed to equilibrate for 1 hour, with flushing and refilling organ
baths with Krebs solution every 15 minutes. Contraction was induced via muscarinic
receptor activation (acetylcholine) at a concentration of 10 µM of acetylcholine (Ach).
Relaxation was measured in response to 10 µM of sodium-nitroprusside (SNP), a NO donor
that induces relaxation. The contractile response of the colonic segments to muscarinic
receptor activation was measured in grams and expressed as mN/100 mg of tissue by
multiplying grams by 9.8 mN. At the end of each experiment, the strips were blotted dry
and weighed (tissue wet weight). The mean tissue weight of 3-month-old control mice was
10.66+1.53 and the mean tissue weight of 3-month-old mdx mice was 10.75+1.38.

2.7 : Measurement of Contraction in Dispersed Smooth Muscle Cells
Contraction in freshly dispersed colonic muscle cells was determined by scanning
micrometry. A cell aliquot consisting of 10-4 cells/ml was treated with 500 µl of medium
containing acetylcholine (ACh, 10 µM) for 30 s or 5 minutes and the reaction was
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terminated with 1% acrolein at a final concentration of 0.1%. Acrolein, which kills and
fixes cells without affecting the cell length. The resting cell length was determined in
control experiments in which muscle cells were incubated with 500 µl of 0.1% bovine
serum albumin without the ACh. The mean lengths of 50 muscle cells treated with
acetylcholine was measured by scanning micrometry and compared with the mean lengths
of untreated cells. The contractile response was expressed as the percent decrease in mean
cell length from control cell length.
Relaxation was measured in intact muscle cells contracted with ACh (1 μM).
Muscle cells were treated for 5 minutes with isoproterenol (10 μM) followed by ACh for
30 s or 5 min. The reaction was terminated with 1% acrolein. The length of 50 cells treated
with acetylcholine was measured in sequential microscopic fields by scanning micrometry.
Relaxation was expressed as percent increase in the length of cells contracted with ACh.

2.8 : Qualitative Real-Time PCR Analysis (qRT-PCR)
To obtain mRNA from colonic tissue, 1 mL of TRIzol reagent was added to ~40100 mg of tissue. The mixture was homogenized via Fisher PowerGen 125 homogenizer.
200 µL of chloroform was added to separate the solution in an aqueous and organic phase.
The RNA remained in the aqueous phase. The solution is vortexed and allowed to incubate
at room temperature for 5 minutes, then centrifuged at 13.3 rpm at 4°C for 15 minutes. The
superior aqueous phase was transferred to a new autoclaved eppendorf tube and 0.5 ml of
isopropanol was added to dissolve any salts that may have chelated on the RNA samples.
The solution is vortexed and centrifuged at 13.3 rpm at 4°C for 20 minutes. The resulting
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supernatant is then discarded, and 1 ml of ethanol is added, allowing precipitation of RNA
out of the aqueous solution. The mixture is centrifuged at 13.3 rpm at 4°C for 10 minutes.
The ethanol was then removed, and the eppendorf tubes are vacuum dried until all liquid
phase contents have been evaporated. Twenty-five microliter of RNase and DNase free
ultrapure distilled water is added and the tubes are allowed to incubate at 65°C for 10
minutes. Concentration was measured using Nanodrop8000.
RNA from each preparation was reversely transcribed using the High Capacity
cDNA reverse transcription kits to prepare the 2x RT Master Mix [10x RT Buffer, 25x
dNTP Mix, 10x RT Random primers, Multiscribe Reverse Transcriptase, Nuclease Free
H2]. An equal volume of RNA was added to 2xRT Master Mix. Quantitative RT-PCR was
then performed on cDNA samples using the specific primers of: Tropomyosin, Caldesmon,
Calponin, and Smoothelin, based on known sequences in mouse and Taqman gene
expression master mix. 18-S and β-actin expression were used as controls to normalize
expression of the target genes. The primers were designed to satisfy the use of 2-∆∆CT
method, which is the standard method of comparing gene expression between two groups.
With 18-S/β-actin acting as controls, a quantitative comparison between mdx, mdx/mTR
and their age-matched control was calculated using the 2-∆∆CT method. Final calculations
were expressed as a fold difference in the expression of mdx, mdx/mTR, and treated
mdx/mTR mice cohorts relative to their age-matched control.

2.9 : Western Blot Analysis
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Colonic tissue, not exceeding 50 mg, were taken from animal models, cleaned and
removed of the mucosa (as aforementioned), and transferred into new eppendorf tubes with
appropriate amounts of 1.44mm beads and TPER (lysis buffer) in the presence of protease
inhibitor. Bead number was calculated as 5 times the tissue weight with TPER volume
being double the tissue weight. Tissues were homogenized using a bullet blender. The
supernatant was collected and centrifuged at 13.3 rpm at 4°C for 10 minutes. Protein
concentration was then measured using a DC protein assay kit from Bio-Rad. Equal
amounts of proteins were fractionated by SDS/PAGE and transferred on to Polyvinylidene
difluoride (PVDF) membrane. Blots were blocked with 1X TBS with 1% casein blocker
for 1 hour at room temperature and then incubated overnight at 4 °C with various primary
antibodies in 1X TBS with 1% casein (Calponin 1:5000, Tropomyosin 1:1000, Caldesmon
1:10,000, Smoothelin 1:5000). After incubation for 1 h with horseradish-peroxidaseconjugated corresponding secondary antibody (1:5000) in 1X TBS with 1% casein,
immunoreactive proteins were visualized using Clarity Max Western ECL Substrate,
Clarity Western ECL Substrate, or SuperSignal West Pico Chemiluminescent Substrate kit.
All washing steps were performed with TBS-T. The protein bands were identified by
enhanced chemiluminescence reagent.

3.0: Statistical Analysis
Data and results are presented as means ± Standard Error Mean (SEM). All
experiments were completed four or more times. Results were analyzed for statistical
significance using unpaired student T tests. p values < 0.05 were considered significant.
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Chapter 3: RESULTS

3.1 Effect of DMD on Smooth Muscle Contraction and Relaxation
To assess the role of what dystrophin loss has on colonic smooth muscle function,
we utilized mdx and mdx/mTR mouse models of that lack dystrophin and express the DMD
phenotype. Effect of H2S treatment on the smooth muscle contractile function in the
mdx/mTR mouse model was assessed. Colonic tissue from mdx/mTR mice treated with
SG1002, an orally active slow-releasing compound that provides stable, non-toxic serum
and tissue levels of H2S. SG1002 is seen to induce cardioprotection in murine models of
DMD; however, its therapeutic potential in the GI tract of DMD mice has not been
evaluated. Colonic tissue from mdx/mTR mice and mdx/mTR mice treated with SG1002
were kindly provided by Dr. Salloum.

Smooth muscle function was measured as

contraction in response to acetylcholine (activator of the main excitatory muscarinic
receptor pathway), and relaxation in response to sodium nitroprusside, nitric oxide (NO)
donor (activator of the main inhibitory nitrergic pathway) and isoproterenol (activator of
inhibitory β-adrenergic pathway). Contraction and relaxation were measured in intact
colonic muscle segments and isolated colonic muscle cells.
Contraction and relaxation in muscle strips. For isometric contractions, intact
colonic segments from mdx mice, mdx/mTR mice, and their age matched control were
placed longitudinally in an organ bath with Krebs buffer. Acetylcholine (ACh, 10 µM) was
administered to induce contraction in the colonic tissues. Force of contraction was
measured in grams. In muscle segments from control mice acetylcholine typically
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produced 0.7±0.2 g of contraction and the contraction was inhibited (0.3±0.1 g) in muscle
segments from mdx mice (Figure 3, left panel). Contraction in grams was normalized to
tissue and presented as mN/100 mg tissue. ACh-induced contractions in colonic muscle
segments from mdx mice was significantly lower compared to their age-matched control
(15.6+3.9 mN/100 mg tissue in control and 3.8+1.4 mN/100 mg tissue in mdx mice;
p<0.05, n=4-5) (Figure 3, right panel).
ACh-induced contraction was also significantly decreased in colonic segments from
mdx/mTR mice compared to their age-matched control (12.4+2.3 mN/100 mg tissue in
control and 4.2+1.3 mN/100 mg tissue in mdx/mTR mice; p<0.05, n=4) (Figure 4).
Although, mdx/mTR mice are shown to exhibit much severe phenotype of DMD, inhibition
of contraction in colonic muscle strips from mdx mice is observed to be slightly greater
than the inhibition in colonic segments mdx/mTR mice (73±6% inhibition in mdx mice
versus 65±6% inhibition in mdx/mTR mice).
Isometric contractions of colonic segments from mdx/mTR mice treated with
SG1002 were also evaluated. Acetylcholine-induced contraction in colonic segments from
mdx/mTR mice treated with SG1002 was significantly improved compared to colonic
segments from mdx/mTR mice (9.2+1.4 mN/100 mg in mdx/mTR mice treated with SG1002
versus 4.2±1.3 in mdx/mTR mice) (Figure 4). The inhibition of contraction in mdx/mTR
mice treated with SG1002 was significantly less compared to mdx/mTR mice (23±5%
inhibition versus 65±6% in mdx/mTR mice. p < 0.01, n=4). These results suggest that H2S
reversed the decrease in smooth muscle contraction in mdx/mTR mice and restored closer
to normal levels.
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Relaxation in response to SNP in muscle strips was measured as inhibition of AChinduced contraction. Muscle strips were treated with ACh (10 µM) and after attaining a
stable contraction, SNP (10 µM) was added to measure relaxation. SNP induced complete
relaxation of ACh-induced contraction in muscle strips from control, mdx and mdx/mTR
mice. There was no significant difference in relaxation in response to SNP between mdx
mice and their age matched control (96±2% in control and 94±3% in mdx mice) and
mdx/mTR mice, mdx/mTR mice (treated with SG1002) and their age-matched control
(125±5% in control mice, 105+10 in mdx/mTR mice and 108±7% in mdx/mTR mice treated
with SG1002) (Figures 5 and 6). These results suggest that relaxation in response to NO
donor was not affected in colonic muscle of mdx and mdx/mTR mice.
Contraction and relaxation in isolated muscle cells. Contraction and relaxation in
response to acetylcholine and SNP in innervated muscle strips could be accredited to the
release of transmitters from enteric neurons and/or to the effect of interstitial cells of Cajal
(ICC) that modulate the intrinsic electrical and mechanical activity of smooth muscles. To
identify the specific involvement of smooth muscle dysfunction to the muscle itself,
colonic muscle cells devoid of enteric neurons and ICC were isolated from mdx mice and
their age-matched controls, and contraction in response to ACh was measured and
expressed as the percent decrease in basal cell length. The kinetic of acetylcholine-induced
contraction consists of an initial Ca++-dependent phase involving activation of
Ca++/calmodulin-dependent MLC kinase and increase in MLC20 phosphorylation and a
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Ca++-independent phase involving inhibition of MLC phosphatase and increase in MLC20
phosphorylation. We measured both initial and sustained contraction in response to ACh
in isolated muscle cells.
The basal cell lengths of colonic smooth muscle cells were not significantly
different in control mice and mdx mice (68±4 µm in control mice and 64±6 µm in mdx
mice). Treatment of cells with ACh for 0.5 min (initial contraction) caused a significant
decrease in muscle cell length both in the colon of control and mdx mice. However, the
contraction in response to ACh was significantly inhibited in muscle cells from colon of
mdx mice compared to control mice (43±5% decrease in cell length in control mice and
25+3% decrease in muscle cell length in mdx mice; p<0.05, n=4-5) (Figure 7). Treatment
of cells with ACh for 5 min (sustained contraction) caused a significant decrease in muscle
cell length both in the colon of control and mdx mice. However, the contraction in response
to ACh was significantly inhibited in muscle cells from colon of mdx mice compared to
control mice (40+4% in control and 27+3 in mdx mice; p<0.05, n=4-5) (Figure 8). The
results in isolated muscle cells are consistent with the results in muscle strips and suggest
that inhibition of contraction in colonic muscle strips is due to a defect in the mechanisms
that regulate contraction intrinsic to smooth muscle cells.
In colonic smooth muscle, inhibitory transmitters that activate cAMP/PKA or
cGMP/PKG pathway cause muscle relaxation. To examine whether the pathways that
mediate relaxation was affected in mdx mice, relaxation was also measured in isolated
smooth muscle cells from the colon of control and mdx mice. To measure relaxation,
muscle cells were pretreated with SNP (10 µM) or isoproterenol (10 µM) and contraction
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in response to ACh (1 µM) was measured. Decrease in ACh-induced contraction in the
presence of SNP or isoproterenol reflects muscle relaxation and it was expressed as percent
inhibition of contraction (i.e., relaxation).

Relaxation in response to SNP was not

significantly different in muscle cells isolated from the colon of control and mdx mice.
SNP caused 83±12% relaxation in muscle cells from control mice and 92±6% relaxation
in muscle cells from mdx mice. (Figure 9). These results suggest that NO-dependent
relaxation mediated via cGMP/PKG pathway was not different in colonic muscle cells
from control versus mdx mice. Isoproterenol also caused 79±6% relaxation in muscle cells
from control mice and 77±5% relaxation in muscle cells from mdx mice. (Figure 10).
These results suggest that G protein-coupled receptor-dependent relaxation mediated via
cAMP/PKA pathway was not different in colonic muscle cells from control versus mdx
mice. The results in isolated muscle cells are consistent with the results in muscle strips
and suggests that intrinsic relaxation mechanisms mediated by cAMP/PKA and
cGMP/PKG pathway are not altered in mdx mice.

3.2 Changes in the Expression of Thin Filament-Associated Proteins
In smooth muscle contraction is mediated by interaction of actin with myosin.
However, this interaction is modulated by thin filament associated proteins. In the present
study, we also analyzed the changes in expression of the thin filament-associated proteins
caldesmon, calponin, tropomyosin, and smoothelin by qRT-PCR and western blot in
smooth muscle of colon isolated from mdx, mdx/mTR, and their age-matched control mice.
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Caldesmon. Caldesmon is a thin-filament associated protein that regulates smooth
muscle contraction via its interaction with actin. Caldesmon has two isoforms, h-caldesmon
that is smooth muscle specific and l-caldesmon that is a non-muscle isoform (Morgan KG,
2001). Expression of caldesmon mRNA was measured using primers specific for smooth
muscle isoform by qRT-PCR in colonic smooth muscle from control and mdx mice and
expressed as fold change from control levels. Expression of caldesmon mRNA was
significantly decreased in colonic smooth muscle from mdx mice compared to control
levels (p <0.05, n=4-5) (Figure 11 Left Panel). Expression of caldesmon protein was
measured using antibodies that are not specific to smooth muscle isoform. Western blot
analysis showed no changes in the expression of caldesmon in colonic smooth muscle
between control and mdx mice (Figure 11 Right Panel).
Expression of caldesmon mRNA was also significantly decreased in mdx/mTR mice
compared to control levels and the decrease in expression was partly reversed by treatment
of mdx/mTR mice with SG1002 (Figure 12). The effect of SG1002 on caldesmon mRNA
expression was significant (p<0.05, n=4).
Calponin: Calponin is another thin filament-associated protein that exists in three
isoforms, h1-acidic, h2-neutral, and basic calponin. The h1-acidic isoform is smoothmuscle specific, whereas the other two are non-muscle isoforms. Expression of calponin
mRNA was measured using primers specific for smooth muscle isoform by qRT-PCR in
colonic smooth muscle from control and mdx mice and expressed as fold change from
control levels. Expression of calponin mRNA was significantly decreased in colonic
smooth muscle from mdx mice compared to control levels (p <0.05, n=4-5) (Figure 13 Left
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Panel). Expression of calponin protein was measured using antibodies that are not specific
to smooth muscle isoform. Western blot analysis showed no changes in the expression of
calponin in colonic smooth muscle between control and mdx mice (Figure 13 Right Panel).
Expression of calponin mRNA was also significantly decreased in mdx/mTR mice
compared to control levels and the decrease in expression was completely reversed by
treatment of mdx/mTR mice with SG1002 (Figure 14). The effect of SG1002 on calponin
mRNA expression was significant (p<0.05, n=4).
Tropomyosin: Tropomyosin, like calponin and caldesmon, is a thin filamentassociated protein that regulates acto-myosin interaction. Two isoforms of tropomyosin
exist, α and β tropomyosin. Expression of tropomyosin mRNA was measured using
primers that are not isoform-specific by qRT-PCR in colonic smooth muscle from control
and mdx mice and expressed as fold change from control levels. Expression of tropomyosin
mRNA was significantly decreased in colonic smooth muscle from mdx mice compared to
control levels (p <0.05, n=4-5) (Figure 15 Left Panel). Expression of the tropomyosin
protein was measured using antibodies that are not isoform-specific. Western blot analysis
showed no changes in the expression of tropomyosin in colonic smooth muscle between
control and mdx mice (Figure 15 Right Panel).
Smoothelin: There are two isoforms of smoothelin, smoothelin-A that is specific to
the visceral smooth muscle and smoothelin-B that is specific to vascular smooth muscle.
Expression of smoothelin-A mRNA was measured using primers that are specific for
visceral smooth muscle by qRT-PCR in colonic smooth muscle from control and mdx mice
and expressed as fold change from control levels. Expression of smoothelin-A mRNA was
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significantly decreased in colonic smooth muscle from mdx mice compared to control
levels (p <0.05, n=4-5) (Figure 16 Left Panel). Expression of smoothelin protein was
measured using antibodies that are not isoform-specific. Western blot analysis showed no
changes in the expression of smoothelin in colonic smooth muscle between control and
mdx mice (Figure 16 Right Panel).
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Figure 3.

Colonic muscle strips were isolated from 3-month old control and mdx mice.

Contraction in response to acetylcholine (10 µM) was measured in organ bath experiments.
Contraction was recorded as increase in grams and calculated as mN/100g mg tissue. Left panel:
Bar graphs of calculated values (n=4-5). Right panel: Representative tracing of acetylcholine-
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induced contraction in colonic muscle strips from control and mdx mice. Contraction was
significantly decreased in mdx mice. ** p <0.05, n=4-5
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Figure 4. Colonic muscle strips were isolated from 9-month old control and mdx/mTR mice and
mdx/mTR mice treated with SG1002, an orally active H2S donor. Contraction in response to
acetylcholine (10 µM) was measured in organ bath experiments. Contraction was recorded as
increase in grams and calculated as mN/100g mg tissue. Contraction was significantly decreased
in mdx/mTR ( ** p <0.05, n=4). Treatment with SG1002 partly and significantly reversed the
inhibition in contraction (## p < 0.05, n=4).
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Figure 5. Colonic muscle strips were isolated from 3-month old control and mdx mice. Relaxation
in response to nitric oxide donor, sodium nitroprusside (SNP, 10 µM) was measured as inhibition
of acetylcholine (10 µM)-induced contraction and calculated as percent inhibition of contraction.
SNP completely inhibited contraction in colonic muscle strips from both control and mdx mice
(n=4-5)
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Figure 6. Colonic muscle strips were isolated from 9-month old control and mdx/mTR mice and
mdx/mTR mice treated with SG1002, an orally active H2S donor. Relaxation in response to nitric
oxide donor, sodium nitroprusside (SNP, 10 µM) was measured as inhibition of acetylcholine (10
µM)-induced contraction and calculated as percent inhibition of contraction. SNP completely
inhibited contraction in colonic muscle strips from control and mdx/mTR mice and in mdx/mTR
mice treated with SG1002 (n=4)
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Figure 7. Smooth muscle cells were isolated from the colon of 3-month old control and mdx mice.
Cells were treated with acetylcholine (1 µM) for 0.5 min and contraction was measured as
decrease in cell length from the basal length (control: 68±4 µm and mdx: 64±6 µM) and expressed
as percent decrease in cell length.

Initial contraction was significantly decreased in mdx mice.

** p <0.05, n=4-5
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Figure 8. Smooth muscle cells were isolated from the colon of 3-month old control and mdx mice.
Cells were treated with acetylcholine (1 µM) for 0.5 min and contraction was measured as
decrease in cell length from the basal length (control: 68±4 µm and mdx: 64±6 µM) and expressed
as percent decrease in cell length.

Sustained contraction was significantly decreased in mdx

mice. ** p <0.05, n=4-5
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Figure 9. Smooth muscle cells were isolated from the colon of 3-month old control and mdx mice.
Relaxation in response to nitric oxide donor, sodium nitroprusside (SNP, 10 µM) was measured as
inhibition of acetylcholine (1 µM)-induced contraction and calculated as percent inhibition of
contraction. SNP-induced relaxation was not different in colonic smooth muscle cells from both
control versus mdx mice (n=4-5)
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Figure 10. Smooth muscle cells were isolated from the colon of 3-month old control and mdx
mice. Relaxation in response to β-adrenergic agonist isoproterenol (10 µM) was measured as
inhibition of acetylcholine (1 µM)-induced contraction and calculated as percent inhibition of
contraction. Isoproterenol-induced relaxation was not different in colonic smooth muscle cells
from both control versus mdx mice (n=4-5)
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Figure 11. Expression of caldesmon in colonic smooth muscle of control and mdx mice Left Panel:
RNA was isolated from colonic smooth muscle of 3-month old control and mdx mice. mRNA
expression of caldesmon was measured using specific primers by quantitative RT-PCR and
expressed as fold change over control. mRNA expression of caldesmon was significantly decreased
in colonic smooth muscle from mdx mice compared to control (** p<0.05, n=4-5). Right panel:
Lysates were prepared from colonic smooth muscle of control and mdx mice and expression of
caldesmon was measured by western blot using specific antibody. Representative western blot
image of 4 separate experiments was shown in the figure. Densitometry analysis of all the images
showed no difference in the expression of caldesmon in colonic smooth muscle between control
and mdx mice.
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Figure 12. Effect of H2S on caldesmon expression in colonic smooth muscle of mdx/mTR mice.
Left Panel: RNA was isolated from colonic smooth muscle of 9-month old control and mdx/mTR
mice and mdx/mTR mice treated with SG1002, an orally active H2S donor mRNA expression of
caldesmon was measured using specific primers by quantitative RT-PCR and expressed as fold
change over control. mRNA expression of caldesmon was significantly decreased in colonic
smooth muscle from mdx/mTR mice compared to control (** p<0.05, n=4). Treatment with SG1002
significantly reversed the inhibition in caldesmon mRNA expression (## p<0.05, n=4).
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Figure 13. Expression of calponin colonic smooth muscle of control and mdx mice Left Panel:
RNA was isolated from colonic smooth muscle of 3-month old control and mdx mice. mRNA
expression of calponin was measured using specific primers by quantitative RT-PCR and expressed
as fold change over control. mRNA expression of calponin was significantly decreased in colonic
smooth muscle from mdx mice compared to control (** p<0.05, n=4-5). Right panel: Lysates
were prepared from colonic smooth muscle of control and mdx mice and expression of calponin
was measured by western blot using specific antibody. Representative western blot image of 4
separate experiments was shown in the figure. Densitometry analysis of all the images showed no
difference in the expression of calponin colonic smooth muscle between control and mdx mice.
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Figure 14. Effect of H2S on calponin expression in colonic smooth muscle of mdx/mTR mice. Left
Panel: RNA was isolated from colonic smooth muscle of 9-month old control and mdx/mTR mice
and mdx/mTR mice treated with SG1002, an orally active H2S donor mRNA expression of calponin
was measured using specific primers by quantitative RT-PCR and expressed as fold change over
control. mRNA expression of calponin was significantly decreased in colonic smooth muscle from
mdx/mTR mice compared to control (** p<0.05, n=4). Treatment with SG1002 significantly
reversed the inhibition in calponin mRNA expression (## p<0.05, n=4).
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Figure 15. Expression of tropomyosin in colonic smooth muscle of control and mdx mice Left
Panel: RNA was isolated from colonic smooth muscle of 3-month old control and mdx mice. mRNA
expression of tropomyosin was measured using specific primers by quantitative RT-PCR and
expressed as fold change over control. mRNA expression of tropomyosin was significantly
decreased in colonic smooth muscle from mdx mice compared to control (** p<0.05, n=4-5). Right
panel: Lysates were prepared from colonic smooth muscle of control and mdx mice and expression
of tropomyosin was measured by western blot using specific antibody. Representative western blot
image of 4 separate experiments was shown in the figure. Densitometry analysis of all the images
showed no difference in the expression of tropomyosin in colonic smooth muscle between control
and mdx mice.
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Figure 16. Expression of smoothelin in colonic smooth muscle of control and mdx mice Left Panel:
RNA was isolated from colonic smooth muscle of 3-month old control and mdx mice. mRNA
expression of smoothelin-A was measured using specific primers by quantitative RT-PCR and
expressed as fold change over control. mRNA expression of smoothelin-A was significantly
decreased in colonic smooth muscle from mdx mice compared to control (** p<0.05, n=4-5). Right
panel: Lysates were prepared from colonic smooth muscle of control and mdx mice and expression
of smoothelin was measured by western blot using specific antibody. Representative western blot
image of 4 separate experiments was shown in the figure. Densitometry analysis of all the images
showed no difference in the expression of smoothelin in colonic smooth muscle between control
and mdx mice.
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Chapter 4: DISCUSSION

Duchenne Muscular Dystrophy is the most common form of inherited muscular
dystrophies that affects 1 in 3300 male births (Yucel et al., 2018). This genetic disorder is
caused by a mutation in the gene located at Xp21 which encodes for the cytoskeleton
protein dystrophin (Yucel et al., 2018). Dystrophin is present in all types of muscles and
immunocytochemical studies have localized that dystrophin to the cytoplasmic surface of
the plasma membrane associating tightly with a complex membrane glycoproteins.
Because of its association with important structural proteins and sequence similarity with
other structural proteins such as α-actinin, dystrophin is suggested to have an important
structural role and provide resilience to the plasma membrane during contraction and
relaxation. Dystrophin a large 427 kD protein. The dystrophin gene is transcribed into
multiple RNA isoforms that show tissue specificity. Byers et al have shown that in SDSPAGE, dystrophin characteristically appears as a doublet in skeletal and cardiac muscle
suggesting different isoforms (Byers 1991). In contrast, dystrophin appears as a single
band in intestinal smooth muscle. The levels of dystrophin in smooth muscle are lower
compared to skeletal muscle (Byers 1991). Electron microscopy and immunofluorescence
studies showed that dystrophin is specifically localized in caveolae this localization is
distinct from the adherent junctions containing β1 integrin, fibronectin and vinculin (Byers
1991) (North et al., 1993). Caveolae are microdomains of the plasma membrane that have
been implicated in Ca++ homeostasis and signal transduction. The ability of caveolae to
64

sequester signaling components are due to the scaffolding properties of main caveolar
protein, cavelin-1. Disruption of dystrophin-glycoprotein complex leads to increased
permeability to Ca++ suggesting an important function of dystrophin in the regulation Ca++
homeostasis.
In smooth muscle, Ca++ and G protein-coupled receptor signaling are not only
important for contraction, but also determine the cell phenotype. Caveolin-1 and the
signaling molecules activated during contraction and relaxation of smooth muscle play an
important in the regulation of expression of contractile protein and maintenance of
contractile phenotype. Loss of caveolin-1 is associated with the decreased smooth muscle
contraction and relaxation and change to proliferative phenotype (Halayko et al., 2005).
The importance of caveolin-1 in signal transduction and its association with dystrophin
highlights the significance of dystrophin in regulation of smooth muscle function.
Smooth muscle contains contractile apparatus consisting thin filaments as polymers
of actin monomers and thick filaments as aggregates of myosin filaments. In addition,
thin-filaments are associated with proteins such as calponin, caldesmon, tropomyosin and
smoothelin. These proteins are shown to play a role in the regulation of acto-myosin
interaction and contraction albeit the exact mechanism of regulation is not clear. For
example, both calponin and caldesmon inhibit acto-myosin interaction and contraction,
whereas smoothelin promotes contraction. Interaction of myosin and actin initiates crossbridge cycling and this interaction is greatly facilitated by phosphorylation of 20 kDa
myosin light chain (MLC20). The levels of MLC20 phosphorylation of are regulated by
MLC kinase and MLC phosphatase. Contractile agonists such as acetylcholine cause an
65

increase cytosolic Ca++ to stimulate Ca++/calmodulin-dependent MLC kinase and a
decrease in MLC phosphatase; both lead to increase in MLC20 phosphorylation.
Initially, DMD was considered predominantly a skeletal muscle disorder, clinically
associated with symptoms such as progressive muscular wasting, waddling gait,
pseudohypertrophy of the calves, and this overall loss of ambulation. Cardiac
complications recently became more prominent, as cardiomyopathy and heart failure
related mortality has increased. However, with advancing age, DMD patients also suffer
from many gastrointestinal complications as well, such as bloating, gastroesophageal
reflux, and highly prevalent, life threatening, constipation. These GI complications have
not yet been systematically evaluated, and there is little scientific information on the
pathophysiology and treatment of these conditions in DMD patients (Lo Cascio et al.,
2016) (Petrof et al., 2002) (Shirokova and Niggli 2013). In DMD patients colonic
dysmotility has been attributed to changes in the peristaltic wave patterns characteristic of
the large intestine.
Colonic motility is regulated by enteric neurons, ICC and smooth muscle cells. In
addition to the smooth muscle, dystrophin is expressed in enteric neurons and ICC
(Vannuchhi et al., 2002). Abnormalities in nitrergic neurotransmission have been
suggested to play a role in altered colonic muscle contraction in innervated colonic muscle
strips from mdx mice (Mule et al., 2010).To our knowledge, there are no studies on the role
of dystrophin in the regulation of colonic smooth muscle function. In the present study we
tested the hypothesis that dystrophin is essential for normal contraction and absence of
dystrophin leads to changes in the expression of contractile proteins and decreased
66

contraction. The present study was undertaken to examine the role of dystrophin using
isolated smooth muscle cells as well as muscle strips from colon of control and two DMD
mouse models, mdx and mdx/mTR. Contraction in response to acetylcholine in muscle
strips and isolated muscle cells from colon of both mdx and mdx/mTR mice was decreased
compared to age-matched controls. Expression of calponin, caldesmon, tropomyosin and
smoothelin mRNA was also decreased in colonic muscle from both mdx and mdx/mTR
mice compared to age-matched controls. These results suggest that changes in smooth
muscle function contributes, in addition to the altered neurotransmission, to altered gut
motility in DMD. This is supported by our functional studies in isolated smooth muscle
cells devoid of enteric neurons and ICC. However, given the expression of dystrophin in
enteric neurons and ICC, we cannot exclude the participation of enteric neurons and ICC
in the altered gut motility in DMD.
Another major finding of this study is that treatment of mdx/mTR mice with H2S donor
restores the mRNA of contractile proteins expression and contractile function similar or
close to control. A novel H2S drug, SG1002, has been recently introduced to attenuate
myocardial cellular damage by increasing antioxidant products. Furthermore, in heart
failure patients SG1002 was seen to increase circulatory bioavailability of NO and H2S
(Allen et al., 2010) (Chahbouni et al., 2010). It is unlikely the effect of H2S is due to rapid
effect on signaling pathways. The long-term treatment with H2S points to its role as antioxidant and regulation of transcription factors such as Nrf2 that are involved in the antioxidation and anti-inflammation (Xie et al., 2016). Among the multiple pathogenic
mechanisms proposed in DMD, oxidative stress and inflammation have been implicated in
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the pathophysiology of disease. In support to this notion, recent studies by Boursereau et
al (2018) have shown that NLRP3 inflammasome is involved in the pathogenesis of DMD
and downregulation of NLRP3 inflammasome decreases DMD phenotype (Boursereau et
al., 2018). Increase in the activities of NFAT, AP-1 and NF-κB that play a role in
inflammation are observed in dystrophic muscle (Evans et al., 2009). Another study
showed that treatment of mdx mice with the anti-oxidant N-acetyl cysteine decreased
oxidative stress and protected the muscle fiber from stretch-induced damage (Hori et al.,
2011). Anti-oxidants such as melatonin and resveratrol have been used to ameliorate the
muscular pathology by scavenging ROS in animal model of DMD (Biggar et al., 2001)
(Merlini et al., 2003) (Wamhoff et al., 2006). More importantly, currently available
treatment options for DMD are glucocorticoids and the most the significant effect of
glucocorticoids is to inhibit expression of inflammatory genes.
In conclusion, our results demonstrate that in mdx and mdx/mTR mice mRNA
expression of thin filament associated proteins are decreased and this is associated with
decrease in smooth muscle contraction. Our results also demonstrate that treatment of
mdx/mTR mice with H2S donor restores expression of proteins and contraction in colonic
smooth muscle. Our study suggests a therapeutic potential of SG1002 on the DMD
phenotype. An important unanswered question remains: what is the effect of absence of
dystrophin on the intrinsic signaling pathways activated by contractile agonists in smooth
muscle cells? The lack of dystrophin is known to alter the Ca++ homeostasis and hence it
is hypothesized that Ca++ regulated activity of MLC kinase and MLC20 phosphorylation
levels are also altered in mdx and mdx/mTR mice leading to decreased muscle contraction.
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Finally, though it is clear dystrophin is an important plasma membrane protein that
provides mechanical stability and its association caveolar proteins caveolin-1 might be
important for contractile phenotype, future studies are required to elucidate the role of
dystrophin in the signaling process that regulate smooth muscle contraction.
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